Anatara Lifesciences (ASX:ANR) - CEO, Steven Lydeamore
CEO, Steven Lydeamore
Source: Anatara Lifesciences
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Anatara Lifesciences (ANR) has been granted an Australian patent covering the formulation for its animal health product, Detach
  • Detach is a non-antibiotic therapy designed to prevent and treat diarrhoea in piglets, using an enzyme extracted from pineapples
  • The granted patent strengthens Anatara’s intellectual property portfolio and will help the company progress product commercialisation opportunities
  • In related news, a study of the company’s formulated feed additive in piglets has begun, with completion set for June
  • Anatara Lifesciences is up 22.22 per cent and trading at 22 cents per share

Anatara Lifesciences (ANR) has been granted an Australian patent covering the formulation for its animal health product, Detach.

The company’s product, Detach, is a non-antibiotic therapy designed to prevent and treat diarrhoea in piglets — known as scour — using the enzyme bromelain, which is extracted from the stems of pineapples. 

The granted patent strengthens Anatara’s intellectual property portfolio for the treatment and prevention of diarrhoea caused by pathogenic microbes. Furthermore, the patent also provides a pathway for the company to continue pursuing commercialisation opportunities for the Detach product. 

The patent will expire on August 24, 2038. 

Anatara’s CEO, Steven Lydeamore, commented on what the granted patent means for the company’s future.

“The granting of the patent secures our intellectual property position and is a significant milestone towards commercialising our Detach animal health product,” he said.

“Scour in piglets is an expensive, debilitating, and in some cases, life-threatening condition, and having a product that is registered for use in Australia, we are well placed to leverage our patent as we work towards a commercial deal,” he added.

In related news, the BONIFF-SMEC piglet challenge study for enterotoxigenic Escherichia Coli has begun at Murdoch University. The study, conducted in partnership with Ridley Corporation, will assess piglets given Anatara’s formulated feed additive, combined with Ridley’s semi-moist extruded creed feed.

The project will investigate the effect that this combined formulation has on the piglets’ health, welfare and performance after weaning. The study is expected to be completed in June 2021. 

Anatara Lifesciences is up 22.22 per cent, trading at 22 cents per share at 10:50 am AEST.

ANR by the numbers
More From The Market Herald
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon

" Little Green Pharma (ASX:LGP) seeks to expand to Greece

Little Green Pharma (ASX:LGP) seeks to expand to Greece

" HeraMED (ASX:HMD) signs “significant milestone” with a Perth hospital

Digital maternity care company HeraMED (ASX:HMD) has hit a "truly significant milestone" with a Perth hospital,…

" ResApp Health (ASX:RAP) signs LOI to launch diagnostic app in the Philippines

ResApp Health (ASX:RAP) smartphone diagnostic test is set to launch in the Philippines through an agreement…

" Emyria (ASX:EMD) set to begin ultra-pure CBD trial

Emyria (ASX:EMD) is set to begin phase one clinical trials of its ultra-pure CBD drug candidate,…